Show simple item record

dc.contributor.authorLøken-Amsrud, Kristin Ingeleiven_US
dc.contributor.authorMyhr, Kjell-Mortenen_US
dc.contributor.authorBakke, Søren Jacoben_US
dc.contributor.authorBeiske, Antonie Giæveren_US
dc.contributor.authorBjerve, Kristian Sen_US
dc.contributor.authorBjørnarå, Bård T.en_US
dc.contributor.authorHovdal, Harald Olaven_US
dc.contributor.authorLilleås, Finnen_US
dc.contributor.authorMidgard, Runeen_US
dc.contributor.authorPedersen, Tomen_US
dc.contributor.authorSaltyte Benth, Jurateen_US
dc.contributor.authorTorkildsen, Øivinden_US
dc.contributor.authorWergeland, Stigen_US
dc.contributor.authorHolmøy, Trygveen_US
dc.PublishedPLoS ONE 2013, 8(1):e54417eng
dc.description.abstractObjective: Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship to disease activity in Norwegian multiple sclerosis (MS) patients. Methods: Prospective cohort study in 88 relapsing-remitting MS (RRMS) patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids (the OFAMS study), before and during treatment with interferon beta. The patients were followed for two years with repeated 12 magnetic resonance imaging (MRI) scans and nine serum measurements of alpha-tocopherol. Results: During interferon beta (IFNB) treatment, each 10 µmol/L increase in alpha-tocopherol reduced the odds (CI 95%) for simultaneous new T2 lesions by 36.8 (0.5–59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6–57.7) %, p = 0.042, in a hierarchical regression model. These associations were not significant prior to IFNB treatment, and were not noticeably changed by gender, age, body mass index, HLA-DRB1*15, treatment group, compliance, or the concentrations of 25-hydroxyvitamin D, retinol, neutralising antibodies against IFNB, or the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid. The corresponding odds for having new T1 gadolinium enhancing lesions two months later was reduced by 65.4 (16.5–85.7) %, p = 0.019, and for new T2 lesions by 61.0 (12.4–82.6) %, p = 0.023. Conclusion: During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients.en_US
dc.rightsAttribution CC BYeng
dc.titleAlpha-tocopherol and MRI outcomes in multiple sclerosis - association and predictionen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2013 The Authors
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Neurology: 752

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY